

Special Issue

The Anglesio Prize in Cancer Epidemiology and Cancer Registration

Message from the Guest Editor

This Special Issue is dedicated to the Winners of the year 2023 Edition of Enrico Anglesio Prize <https://www.fondoeelenamoroni.org/en/the-prize/>. This International Prize is awarded to young researchers for their original work in cancer epidemiology, and cancer registration. Evaluation was based on scientific relevance, originality, methodological correctness and how the study message was delivered. The year 2023 Edition proposes studies tackling novel methods that, with the help of Artificial Intelligence, aim to detect rare but adverse events among cancer survivors. It is well known that cancer incidence, but also survival, can be affected by factors that are outside the realm of treatment and health care, but are equally important, such as inequality in socio-economic factors and factors that impact all of society, as demonstrated by COVID-19. Measuring the effect of such factors on survival or quality of life and health care is still an important mission of epidemiological studies.

Guest Editor

Dr. Stefano Rosso

Piedmont Cancer Registry, Department of Medical Science, University of Turin, 10123 Turin, Italy

Deadline for manuscript submissions

closed (30 April 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/188829

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)